| MeSH term | MeSH ID | Detail |
|---|---|---|
| Celiac Disease | D002446 | 16 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Cholelithiasis | D002769 | 16 associated lipids |
| Cholestasis | D002779 | 23 associated lipids |
| Chondrodysplasia Punctata | D002806 | 8 associated lipids |
| Chronic Disease | D002908 | 7 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Coronary Artery Disease | D003324 | 47 associated lipids |
| Coronary Disease | D003327 | 70 associated lipids |
| Demyelinating Diseases | D003711 | 15 associated lipids |
(e,e,e,e)-squalene
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
Cross Reference
Introduction
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with (e,e,e,e)-squalene?
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
PubChem Associated disorders and diseases
What pathways are associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with (e,e,e,e)-squalene?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with (e,e,e,e)-squalene?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with (e,e,e,e)-squalene
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sarpietro MG et al. | Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. | 2011 | Int J Pharm | pmid:21219999 |
| Brasser AJ et al. | Presence of wax esters and squalene in human saliva. | 2011 | Arch. Oral Biol. | pmid:21247555 |
| Arguedas A et al. | Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. | 2011 | Hum Vaccin | pmid:21285531 |
| Manuel O et al. | Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. | 2011 | Clin. Infect. Dis. | pmid:21288852 |
| Alghisi F et al. | Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. | 2011 | Thorax | pmid:21228426 |
| Decaro N et al. | Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. | 2011 | Vaccine | pmid:21272607 |
| Arias JL et al. | Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. | 2011 | ACS Nano | pmid:21275408 |
| van den Brand JM et al. | Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. | 2011 | J. Virol. | pmid:21209108 |
| Calabro S et al. | Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. | 2011 | Vaccine | pmid:21215831 |
| Javelle E et al. | Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. | 2011 | Vaccine | pmid:21172376 |
| Montagnani S et al. | Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. | 2011 | Ann Pharmacother | pmid:21189364 |
| Esposito S et al. | Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. | 2011 | Vaccine | pmid:21199699 |
| Lopez P et al. | Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. | 2011 | J. Infect. Dis. | pmid:21606530 |
| Pariani E et al. | Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. | 2011 | Vaccine | pmid:21974995 |
| Andrews NJ et al. | Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. | 2011 | Vaccine | pmid:21875635 |
| Vesikari T et al. | Oil-in-water emulsion adjuvant with influenza vaccine in young children. | 2011 | N. Engl. J. Med. | pmid:21995388 |
| Bernstein DI | Vaccines for cytomegalovirus. | 2011 | Infect Disord Drug Targets | pmid:22309618 |
| Fabbiani M et al. | Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. | 2011 | Vaccine | pmid:21349364 |
| Gill S et al. | Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. | 2011 | Cell Metab. | pmid:21356516 |
| Niehaus TD et al. | Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21746901 |
| Cheong HJ et al. | Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. | 2011 | Clin. Vaccine Immunol. | pmid:21715575 |
| Soto G et al. | Acetoacetyl-CoA thiolase regulates the mevalonate pathway during abiotic stress adaptation. | 2011 | J. Exp. Bot. | pmid:21908473 |
| Oliaro-Bosso S et al. | Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase. | 2011 | PLoS ONE | pmid:21811565 |
| Bildstein L et al. | Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. | 2011 | Eur J Pharm Biopharm | pmid:21784150 |
| Della Cioppa G et al. | Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. | 2011 | Vaccine | pmid:21906647 |
| Fox CB et al. | Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. | 2011 | Vaccine | pmid:21906648 |
| Zuccotti GV et al. | Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. | 2011 | Diabet. Med. | pmid:21916971 |
| Meyer K et al. | A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. | 2011 | PLoS ONE | pmid:21887300 |
| Broeders NE et al. | Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. | 2011 | Clin J Am Soc Nephrol | pmid:21921153 |
| Achiraman S et al. | Increased squalene concentrations in the clitoral gland during the estrous cycle in rats: an estrus-indicating scent mark? | 2011 | Theriogenology | pmid:21924481 |
| Brito LA et al. | An alternative renewable source of squalene for use in emulsion adjuvants. | 2011 | Vaccine | pmid:21723355 |
| Weyermann C et al. | Initial results on the composition of fingerprints and its evolution as a function of time by GC/MS analysis. | 2011 | J. Forensic Sci. | pmid:20707835 |
| Wu J et al. | Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. | 2011 | Arch. Virol. | pmid:21110049 |
| Packwood DM and Phillips LF | A stochastic, local mode study of neon-liquid surface collision dynamics. | 2011 | Phys Chem Chem Phys | pmid:21042647 |
| Tabache F et al. | Acute polyarthritis after influenza A (H1N1) immunization. | 2011 | Joint Bone Spine | pmid:21444232 |
| Sun Y et al. | A reproducible in-vivo model of lymphatic malformation in rats. | 2011 | J. Comp. Pathol. | pmid:21419420 |
| Meier S et al. | Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. | 2011 | Vaccine | pmid:21419775 |
| Réjiba S et al. | Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. | 2011 | Nanomedicine | pmid:21419876 |
| Banzhoff A et al. | Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. | 2011 | Hum Vaccin | pmid:21422814 |
| Parretta E et al. | Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. | 2011 | Vaccine | pmid:21406267 |
| Ambike A et al. | Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. | 2011 | Langmuir | pmid:21413743 |
| Gao J et al. | Laser-induced acoustic desorption/atmospheric pressure chemical ionization mass spectrometry. | 2011 | J. Am. Soc. Mass Spectrom. | pmid:21472571 |
| Weschler CJ et al. | Squalene and cholesterol in dust from danish homes and daycare centers. | 2011 | Environ. Sci. Technol. | pmid:21476540 |
| Cauda V et al. | "Liquid-phase calcination" of colloidal mesoporous silica nanoparticles in high-boiling solvents. | 2011 | J. Am. Chem. Soc. | pmid:21480591 |
| Griffiths PD et al. | Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. | 2011 | Lancet | pmid:21481708 |
| Liu CL et al. | The direct observation of secondary radical chain chemistry in the heterogeneous reaction of chlorine atoms with submicron squalane droplets. | 2011 | Phys Chem Chem Phys | pmid:21455529 |
| Inagaki YS et al. | Investigation of the potential for triterpene synthesis in rice through genome mining and metabolic engineering. | 2011 | New Phytol. | pmid:21501172 |
| Garcia-Sicilia J et al. | Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. | 2011 | Vaccine | pmid:21504774 |
| O'Hagan DT et al. | MF59 adjuvant: the best insurance against influenza strain diversity. | 2011 | Expert Rev Vaccines | pmid:21506643 |
| Esposito S et al. | Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. | 2011 | Hum Vaccin | pmid:21508673 |